Cardiovascular disease Archives

News and Trends 8 Nov 2016

These companies want to use Stem Cells to improve Drug Safety

Axiogenesis and Metrion Biosciences will use stem cells to improve preclinical neurotoxicity and cardiac safety testing, a feat that can significantly reduce the time and cost of drug discovery and clinical development. Axiogenesis is a Biotech from Cologne, Germany, that develops cell lines derived from induced pluripotent stem cells (iPSCs) for preclinical applications. The company […]

November 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 11 01 at 3.27.32 PM e1478010517232

News and Trends 1 Nov 2016

Novo Nordisk pressured into Dropping Needle-Free Oral Insulin

Needle-free diabetes will have to wait: payers are pressuring pharma to provide lower medication prices, and Novo Nordisk has responded by redirecting its R&D strategy into more innovative research. Despite its position as a world leader in diabetes, Novo Nordisk seems to be hitting a rough patch: the big pharma is reducing its profit and […]

November 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Aug 2016

Inotrem on its way to Control Acute Inflammation

We leave the North of Spain, meander through the Pyrenees and prendons un verre du vin français before arriving in Nancy. Here, we can visit the city’s UNESCO World Heritage Site and have a good quiche Lorraine. Then, it’s time to head to Inotrem, our Biotech of the Week. City: Nancy, France Founded: 2013 Employees: 12 Financial Data: €18M […]

August 19, 2016 - 1 minutemin - By Denise Neves Gameiro

News and Trends 27 Jul 2016

AstraZeneca plans Phase I trial with mRNA therapy for Cardiovascular Disease

The collaboration between AstraZeneca and the money-magnet Moderna is giving its first steps. AstraZeneca is filing for authorization of a German Phase I trial, to assess an mRNA therapy for cardiometabolic diseases. Therapies using mRNA have a lot of potential as biologics. Leading Biotechs in the field include CureVac (interview with its CCO here) and […]

July 27, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 21 Jul 2016

Biotech-funded ‘Angels Initiative’ wants to create 1500 Stroke centres across Europe

Boehringer Ingelheim is funding a new initiative to tackle stroke in Europe, a leading cause of disability and death. Together with the European Stroke Organisation, it aims to have 1500 new stroke-ready centres by 2019. Cardiovascular diseases are now the #1 cause of death all over the world, killing an estimated 17.5 million people according to the […]

July 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 29 Jun 2016

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

AFFiRiS has received €10M from previous investors and one additional backer, adding up to €130M in total funding (half from grants and licensing incomes). This money fuels a pipeline in cardiometabolic and neurodegenerative diseases as more candidates break into clinical development. Based at the Campus Vienna Biocenter (Austria), AFFiRiS is developing immunotherapies to prevent chronic diseases. […]

June 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 29 Jun 2016

Cell Therapy for Heart Failure fails in Phase III … but not Entirely

Celyad failed to get significant results in its Phase III trial in cardiac disease. However, this cell therapy could still have a positive effect in a part of the patients. True potential or public relations patch? Cardiovascular diseases are the leading cause of death worldwide. Biotech solutions in the field range from gene therapy (with uniQure and […]

June 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 9 Jun 2016

German Biotech launches Phase II in a hot Target for Inflammation

InflaRx has treated the first patient in a new Phase II trial, which is studying the potential of its anti-complement antibody in avoiding immunological complications after complex cardiac surgery – a big unmet need. It is competing with world most expensive drug Soliris from Alexion (US). Based in Jena (Germany), InflaRx specializes in developing new […]

June 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 11 Apr 2016

Swedish Startup close to the North Pole signs 100 million deal with AstraZeneca

Lipigon Pharmaceuticals will now count with AstraZeneca to push the development of its Lipoprotein Lipase strategies. This could produce novel drugs to tackle metabolic and cardiovascular disease, still the leading cause of death worldwide. Lipigon is a spinout of Umeå University, developing new drugs based on research of lipid metabolism. Umeå may have one of the most remote universities […]

April 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 16 Mar 2016

‘Cyborg’ Heart Patch to Revolutionize Treatment of Heart Attacks

Researchers from Tel Aviv University (Israel) have managed to engineer a Nanotech ‘heart patch’ which could enable remote monitoring and regulation of a patient’s heart – bionic! MedTech continues to blur the boundary between man and machine. A new project combines organic, living tissue and a complex nanoelectronic system to create a bionic heart patch that could help […]

March 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Mar 2016

Artificial Hearts are one Step Closer to the Market with €50M in Funding

Carmat (France) has raised €50M from private investors (dwarfing its 2015’s €3M reserves) in order to further develop its artificial hearts during 2016 and apply for CE Marking. This French Medtech company is developing an artificial heart (one of top examples of futuristic cyborg-like technologies in biotech) that could help patients with end-stage biventricular heart failure. There are people […]

March 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 22 Feb 2016

This German Biotech had to stop its EU Phase III Trial for Lack of Recruitment

The Aachen-based pharma Paion (Germany), has been forced to axe a European phase III trial for a Surgical sedative, after failing to recruit enough patients. The company will instead focus its efforts on its ongoing US trials. This is a blow to Paion’s pipeline, which is led by Remimazolam. The company stock price decreased almost 40%, but it […]

February 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cardiovascular disease

These companies want to use Stem Cells to improve Drug Safety

Novo Nordisk pressured into Dropping Needle-Free Oral Insulin

Inotrem on its way to Control Acute Inflammation

AstraZeneca plans Phase I trial with mRNA therapy for Cardiovascular Disease

Biotech-funded ‘Angels Initiative’ wants to create 1500 Stroke centres across Europe

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

Cell Therapy for Heart Failure fails in Phase III … but not Entirely

German Biotech launches Phase II in a hot Target for Inflammation

Swedish Startup close to the North Pole signs 100 million deal with AstraZeneca

‘Cyborg’ Heart Patch to Revolutionize Treatment of Heart Attacks

Artificial Hearts are one Step Closer to the Market with €50M in Funding

This German Biotech had to stop its EU Phase III Trial for Lack of Recruitment

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!